Insiders Are Spending Big: 15 Stocks Leading in March

11. Zymeworks Inc. (NASDAQ:ZYME)

Total Value of Insider Purchases In March: $15.99 million

Market Capitalization: $889.89 million

Zymeworks is a clinical-stage biopharmaceutical company that develops biotherapeutics for cancer treatment, with lead candidates including zanidatamab, a human epidermal growth factor receptor 2 (HER2) in Phases 1-3 clinical trials, and zanidatamab zovodotin, a Phase 2 HER2-targeted antibody-drug conjugate. The Middletown, Delaware-based company also explores preclinical oncology programs and collaborates with partners like BeiGene, Celgene, GlaxoSmithKline, and Merck Sharp & Dohme, among others.

For the full year 2024, Zymeworks reported revenue of $76.3 million, compared to $76.0 million in 2023. Revenue for 2024 included $25.0 million in milestone revenue from Jazz related to FDA approval of Ziihera (zanidatamab-hrii) for HER2+ BTC treatment. Research and development expense was $134.6 million in 2024 compared to $143.6 million in 2023. Net loss was $122.7 million in 2024 compared to a $118.7 million loss in 2023. As of December 31, the company had $324.2 million of cash resources consisting of cash, cash equivalents and marketable securities.

In March, one insider purchased a total of $15.99 million Zymeworks shares at an average price of $12.29 per share. The stock trades at $12.96 having declined 11.48% year-to-date. However, over the past 12 months, its shares returned 20.56% to investors.

According to six analysts, Zymeworks stock has an average rating of “Buy,” with a price target of $19.50, indicating a 50.93% upside from the latest price, writes StockAnalysis.